Jump to control PDSP data

JNJ-9350

Compound concentration: 10 µM

Receptor	HGNC target name	Inhibition [%] (Primary experimental value)	Ki [nM] (Secondary experimental value)	pKi
5-HT1A	HTR1A	13.07
5-HT1E	HTR1E	0.95
5-HT2A	HTR2A	27.36
5-HT2B	HTR2B	57.92	897.02	6.05
5-HT2C	HTR2C	28.43
5-HT3	HTR3A	25.64
5-HT5A	HTR5A	17.54
5-HT6	HTR6	-12.43
5-HT7A	HTR7	8.26
Alpha1A	ADRA1A	3.52
Alpha1B	ADRA1B	10.25
Alpha1D	ADRA1D	28.06
Alpha2A	ADRA2A	64.00	3826.48	5.42
Alpha2B	ADRA2B	42.24	3579.32	5.45
Alpha2C	ADRA2C	20.08
Beta1	ADRB1	2.96
Beta2	ADRB2	-4.50
GABAA/BZP		-16.10
D1	DRD1	28.93
D2	DRD2	25.33
D3	DRD3	40.47
D4	DRD4	20.91
D5	DRD5	20.40
DAT	SLC6A3	47.72
DOR	OPRD1	17.15
H1	HRH1	4.87
H3	HRH3	-7.55
H4	HRH4	32.65
KOR	OPRK1	73.33	1168.96	5.93
M1	CHRM1	24.76
M2	CHRM2	24.29
M3	CHRM3	31.99
M4	CHRM4	36.60
M5	CHRM5	37.91
MOR	OPRM1	24.77
NET	SLC6A2	46.02
GABA/PBR		114.10	497.62	6.30
SERT	SLC6A4	16.60
Sigma 1	SIGMAR1	30.52
Sigma 2	TMEM97	76.70	1924.86	5.72
5-HT1B	HTR1B	103.72	477.93 average (n=2)	6.39
5-HT1D	HTR1D	100.58	219.42 average (n=2)	6.71
Beta3	ADRB3	-7.92
H2	HRH2	26.91

JNJ-4545

Compound concentration: 10 µM

Receptor	HGNC target name	Inhibition [%] (Primary experimental value)	Ki [nM] (Secondary experimental value)	pKi
H2	HRH2	10.75
Beta3	ADRB3	-5.81
5-HT1B	HTR1B	38.40
5-HT1D	HTR1D	48.54
5-HT1A	HTR1A	16.49
5-HT1E	HTR1E	15.07
5-HT2A	HTR2A	17.84
5-HT2B	HTR2B	17.48
5-HT2C	HTR2C	7.86
5-HT3	HTR3A	16.19
5-HT5A	HTR5A	6.76
5-HT6	HTR6	-8.97
5-HT7A	HTR7	0.12
Alpha1A	ADRA1A	-7.41
Alpha1B	ADRA1B	75.32	9783.63	5.01
Alpha1D	ADRA1D	39.32
Alpha2A	ADRA2A	28.14
Alpha2B	ADRA2B	10.80
Alpha2C	ADRA2C	-1.48
Beta1	ADRB1	4.27
Beta2	ADRB2	-7.96
GABAA/BZP		25.92
D1	DRD1	22.71
D2	DRD2	32.17
D3	DRD3	89.96	3603.30	5.44
D4	DRD4	89.30	3385.32	5.47
D5	DRD5	14.96
DAT	SLC6A3	79.87	6549.38	5.18
DOR	OPRD1	49.26
H1	HRH1	14.95
H3	HRH3	6.04
H4	HRH4	27.93
KOR	OPRK1	90.74	197.79	6.70
M1	CHRM1	18.51
M2	CHRM2	46.12
M3	CHRM3	33.49
M4	CHRM4	51.65	1307.68	5.88
M5	CHRM5	30.34
MOR	OPRM1	25.42
NET	SLC6A2	49.42
GABA/PBR		96.59	306.41	6.51
SERT	SLC6A4	12.89
Sigma 1	SIGMAR1	21.23
Sigma 2	TMEM97	25.38

Jump to PDSP top

JNJ-9350

For the selectivity screen 10 µM compound was used.

Conclusion: Closest off-targets are ADORA1 (98.93 % inh.), ADORA2A (74.96 % inh.) and ADORA3 (75.06 % inh.)

Target protein	HGNC name	Species	% inhibition at 10 µM	Mode of action
5-HT1B (h)	HTR1B	Homo sapiens	62.1	antagonist
5-HT2A (h)	HTR2A	Homo sapiens	69.9	agonist
5-HT2B (h)	HTR2B	Homo sapiens	68.5	agonist
A1 (h)	ADORA1	Homo sapiens	98.9	antagonist
A2A (h	ADORA2A	Homo sapiens	75.0	agonist
A3 (h)	ADORA3	Homo sapiens	75.1	agonist
CCK1 (CCKA) (h)	CCKAR	Homo sapiens	70.3	agonist
kappa (h) (KOP)	OPRK1	Homo sapiens	74.1	agonist
M4 (h)	CHRM4	Homo sapiens	59.8	antagonist
MT1 (ML1A) (h)	MTNR1A	Homo sapiens	58.8	agonist
NK2 (h)	TACR2	Homo sapiens	56.8	agonist
PDE4D2 (h)	PDE4D	Homo sapiens	63.1
sigma  (non-selective) (h)		Homo sapiens	62.8	agonist